Endothelial Cell Stimulator of Interferon Genes Regulates IL-6 Production and Is Required for Pathologic Cardiac

Erin Sanders1, Kuljeet Kaur2, Noah Wagner2

  • 1Department of Immunology, Tufts University School of Medicine, Boston, Massachusetts; Tufts Graduate School of Biomedical Sciences, Boston, Massachusetts.

Insights

Stimulator of interferon genes (STING) in cardiac endothelial cells (ECs) drives heart failure by promoting cardiomyocyte hypertrophy and capillary rarefaction. Blocking EC STING improves cardiac function in experimental heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Immunology

Background:

  • Heart failure (HF) involves capillary rarefaction and cardiomyocyte (CM) hypertrophy.
  • Molecular signaling in cardiac cells is crucial for HF pathophysiology.
  • The stimulator of interferon genes (STING) pathway's role in cardiac cells is largely unexplored.

Purpose of the Study:

  • To investigate the role of STING in cardiac endothelial cells (ECs) during heart failure.
  • To determine if EC STING contributes to cardiac dysfunction, CM hypertrophy, and capillary rarefaction.

Main Methods:

  • Utilized global and EC-specific STING knockout mouse models.
  • Induced experimental heart failure via transverse aortic constriction (TAC).
  • Analyzed cardiac function, CM size, capillary density, gene expression, and cell-cell communication (CellChat).

Main Results:

  • STING is upregulated in cardiac ECs during HF and is essential for contractile dysfunction in TAC mice.
  • EC STING deficiency prevents TAC-induced CM hypertrophy and capillary rarefaction.
  • STING activation in ECs promotes IL-6 secretion, which drives CM hypertrophy in a STING-dependent manner.

Conclusions:

  • Cardiac EC STING is a critical mediator of HF pathophysiology.
  • Targeting EC STING may offer a novel therapeutic strategy for heart failure.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
51
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
35
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
62
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
516